Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma

Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma

(2018) Yubing Zhou et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells

(2018) Tang Liu et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

(2018) Nathalie Gaspar et al.   EUROPEAN JOURNAL OF CANCER

Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53’s tumor suppression

(2018) Józefa Węsierska-Gądek   Future Medicinal Chemistry

Kinase-targeted cancer therapies: progress, challenges and future directions

(2018) Khushwant S. Bhullar et al.   Molecular Cancer

Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non–Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing

(2018) Zahra Shajani-Yi et al.   NEOPLASIA

Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma

(2018) Nan Kang et al.   BMC CELL BIOLOGY

Mutant p53 as a target for cancer treatment

(2017) Michael J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

MicroRNA-503 suppresses cell proliferation and invasion in osteosarcoma via targeting insulin-like growth factor 1 receptor

(2017) Zili Wang et al.   Experimental and Therapeutic Medicine

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations

(2016) M. Bousquet et al.   ANNALS OF ONCOLOGY

Mutation R273H confers p53 a stimulating effect on the IGF-1R-AKT pathway via miR-30a suppression in breast cancer

(2016) Fangdong Guo et al.   BIOMEDICINE & PHARMACOTHERAPY

Survivin: a unique target for tumor therapy

(2016) Himani Garg et al.   Cancer Cell International

TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data

(2016) Zhe Chen et al.   DISEASE MARKERS

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

(2016) Neyssa M Marina et al.   LANCET ONCOLOGY

p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines

(2015) Shunan Ye et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53

(2015) Shengliang Zhang et al.   CANCER RESEARCH

An update on chemotherapy for osteosarcoma

(2015) Stefano Ferrari et al.   EXPERT OPINION ON PHARMACOTHERAPY

Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo

(2015) Xingxing He et al.   Scientific Reports

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy

(2014) Jie Li et al.   HUMAN MUTATION

Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma

(2014) Xiang Chen et al.   Cell Reports

Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience

(2013) Sarah E. S. Leary et al.   CANCER

High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort

(2013) Gillian Mitchell et al.   PLoS One

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis

(2012) Jiangbo Liu et al.   EUROPEAN JOURNAL OF CANCER

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Sarcomas in TP53 germline mutation carriers

(2011) Simona Ognjanovic et al.   CANCER

Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients

(2011) Xing Wu et al.   Cancer Epidemiology

Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil

(2010) Ana Luiza Seidinger et al.   CANCER

p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma

(2010) Brendan Doyle et al.   JOURNAL OF PATHOLOGY

Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines

(2009) Z. Duan et al.   MOLECULAR CANCER THERAPEUTICS